85,580 Shares in Puma Biotechnology, Inc. (NASDAQ:PBYI) Acquired by Marshall Wace LLP

Marshall Wace LLP acquired a new position in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 85,580 shares of the biopharmaceutical company's stock, valued at approximately $261,000. Marshall Wace LLP owned about 0.17% of Puma Biotechnology as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Walleye Capital LLC purchased a new stake in Puma Biotechnology in the fourth quarter worth approximately $118,000. XTX Topco Ltd lifted its stake in Puma Biotechnology by 126.2% in the fourth quarter. XTX Topco Ltd now owns 59,674 shares of the biopharmaceutical company's stock worth $182,000 after purchasing an additional 33,290 shares during the last quarter. Barclays PLC lifted its stake in Puma Biotechnology by 13.3% in the fourth quarter. Barclays PLC now owns 88,407 shares of the biopharmaceutical company's stock worth $270,000 after purchasing an additional 10,386 shares during the last quarter. Kennedy Capital Management LLC boosted its position in Puma Biotechnology by 36.5% during the fourth quarter. Kennedy Capital Management LLC now owns 809,375 shares of the biopharmaceutical company's stock valued at $2,469,000 after buying an additional 216,329 shares during the period. Finally, LSV Asset Management grew its stake in shares of Puma Biotechnology by 75.7% during the fourth quarter. LSV Asset Management now owns 53,400 shares of the biopharmaceutical company's stock valued at $163,000 after buying an additional 23,000 shares during the last quarter. 61.29% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

PBYI has been the subject of several analyst reports. HC Wainwright restated a "buy" rating and set a $7.00 target price on shares of Puma Biotechnology in a report on Friday, February 28th. StockNews.com cut shares of Puma Biotechnology from a "strong-buy" rating to a "buy" rating in a report on Saturday, May 3rd.

Puma Biotechnology Trading Down 5.2 %

Shares of Puma Biotechnology stock traded down $0.16 during midday trading on Friday, reaching $2.91. 475,098 shares of the company's stock traded hands, compared to its average volume of 442,697. The company has a market cap of $144.43 million, a PE ratio of 6.06 and a beta of 1.29. The stock has a 50 day moving average of $3.11 and a 200-day moving average of $3.04. Puma Biotechnology, Inc. has a 12 month low of $2.23 and a 12 month high of $5.20. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.40 and a current ratio of 1.42.

Puma Biotechnology (NASDAQ:PBYI - Get Free Report) last posted its earnings results on Thursday, February 27th. The biopharmaceutical company reported $0.39 EPS for the quarter, topping the consensus estimate of $0.10 by $0.29. Puma Biotechnology had a net margin of 9.56% and a return on equity of 41.60%. The firm had revenue of $59.10 million during the quarter, compared to analysts' expectations of $52.50 million. As a group, equities analysts expect that Puma Biotechnology, Inc. will post 0.31 EPS for the current fiscal year.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.